<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812951</url>
  </required_header>
  <id_info>
    <org_study_id>CSA2020</org_study_id>
    <nct_id>NCT04812951</nct_id>
  </id_info>
  <brief_title>Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery</brief_title>
  <acronym>CSA2020</acronym>
  <official_title>Cyclosporine 0.1% Eye Drops as Prophylactic Treatment in Post Surgical Ocular Surface System Failure Within The Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of Cyclosporine 0.1% Eye Drops as Prophylactic Treatment in cataract Surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To asses ocular discomfort symptoms and signs and inflammatory biomarkers after preoperative&#xD;
      topical cyclosporine 0.1% eye drops therapy in high risk elder population after a specific&#xD;
      insult such as cataract surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 18, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms Assessment Questionnaire iN Dry Eye</measure>
    <time_frame>4 months</time_frame>
    <description>SANDE (frequency and severity scores; 0-100)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>National Eye Institute grading scale</measure>
    <time_frame>4 months</time_frame>
    <description>NEI corneal staining ( n/15 score; 0-15)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of tears' production</measure>
    <time_frame>4 months</time_frame>
    <description>Schirmer test (mm/5min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tears Break Up Time</measure>
    <time_frame>4 months</time_frame>
    <description>T-BUT (Seconds)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers' expression in conjunctival epithelial cells</measure>
    <time_frame>4 months</time_frame>
    <description>HLA DR (molecular expression)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers' expression in conjunctival epithelial cells</measure>
    <time_frame>4 months</time_frame>
    <description>ICAM-1 (molecular expression)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ocular Surface Disease</condition>
  <condition>Ocular Inflammation</condition>
  <arm_group>
    <arm_group_label>young control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>25 patients &lt; 65 years old without any prophylactic anti-inflammatory preoperative treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>25 patients &gt; 75 years old without any prophylactic anti-inflammatory preoperative treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 patients &gt; 75 years old with prophylactic anti-inflammatory preoperative treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 patients &gt; 75 years old with vehicle preoperative treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion</intervention_name>
    <description>one cyclosporine 0.1% eye drop twice a day for 30 preoperative days</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Ikervis eye drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cationorm eye drops</intervention_name>
    <description>one cationorm eye drop twice a day for 30 preoperative days</description>
    <arm_group_label>Vehicle group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  Postmenopausal women for whom cataract surgery has been scheduled&#xD;
&#xD;
          -  Stage N2-3; C1-2 according (Lens Opacities classification System) LOCS&#xD;
&#xD;
          -  Willing to sign informed consent and fully participate to all length of the study&#xD;
&#xD;
          -  Patients without any previous medical history of ocular and/or systemic inflammatory,&#xD;
             autoimmune or auto inflammatory disease&#xD;
&#xD;
          -  Patient with no history of ocular surgery&#xD;
&#xD;
          -  Patients without any previous or concomitant ocular diseases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under topical or systemic anti- inflammatory drugs Patients with a&#xD;
             concomitant diagnosis of glaucoma, or on therapy with antiglaucoma drugs&#xD;
&#xD;
          -  Patients on systemic or local therapy with drugs that alter the secretion of the tear&#xD;
             film (beta blockers, antidepressants and psychotropics)&#xD;
&#xD;
          -  Patients with a history of allergic, congenital, autoimmune systemic diseases&#xD;
&#xD;
          -  Patients who have undergone previous eye surgery&#xD;
&#xD;
          -  Ocular or peri-ocular malignancies or premalignant conditions&#xD;
&#xD;
          -  Active or suspected ocular or peri-ocular infection.&#xD;
&#xD;
          -  Complicated Cataract Surgery&#xD;
&#xD;
          -  Patients with a positive pregnancy testAllergy or reaction history to study drug&#xD;
&#xD;
          -  Patients who participated in a clinical trial in which an investigational drug was&#xD;
             administered within 30 days or 5 half-lives of the study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Di Zazzo</last_name>
    <phone>003906225418893</phone>
    <email>a.dizazzo@unicampus.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Campus Bio Medico</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Di Zazzo</last_name>
      <phone>003906225418893</phone>
      <email>a.dizazzo@unicampus.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Gupta PK, Drinkwater OJ, VanDusen KW, Brissette AR, Starr CE. Prevalence of ocular surface dysfunction in patients presenting for cataract surgery evaluation. J Cataract Refract Surg. 2018 Sep;44(9):1090-1096. doi: 10.1016/j.jcrs.2018.06.026. Epub 2018 Aug 2.</citation>
    <PMID>30078540</PMID>
  </reference>
  <reference>
    <citation>Kim JS, Lee H, Choi S, Kim EK, Seo KY, Kim TI. Assessment of the Tear Film Lipid Layer Thickness after Cataract Surgery. Semin Ophthalmol. 2018;33(2):231-236. doi: 10.1080/08820538.2016.1208764. Epub 2016 Sep 14.</citation>
    <PMID>27627886</PMID>
  </reference>
  <reference>
    <citation>Trattler WB, Majmudar PA, Donnenfeld ED, McDonald MB, Stonecipher KG, Goldberg DF. The Prospective Health Assessment of Cataract Patients' Ocular Surface (PHACO) study: the effect of dry eye. Clin Ophthalmol. 2017 Aug 7;11:1423-1430. doi: 10.2147/OPTH.S120159. eCollection 2017.</citation>
    <PMID>28848324</PMID>
  </reference>
  <reference>
    <citation>Iglesias E, Sajnani R, Levitt RC, Sarantopoulos CD, Galor A. Epidemiology of Persistent Dry Eye-Like Symptoms After Cataract Surgery. Cornea. 2018 Jul;37(7):893-898. doi: 10.1097/ICO.0000000000001491.</citation>
    <PMID>29504953</PMID>
  </reference>
  <reference>
    <citation>Kohli P, Arya SK, Raj A, Handa U. Changes in ocular surface status after phacoemulsification in patients with senile cataract. Int Ophthalmol. 2019 Jun;39(6):1345-1353. doi: 10.1007/s10792-018-0953-8. Epub 2018 Jun 20.</citation>
    <PMID>29926365</PMID>
  </reference>
  <reference>
    <citation>Kasetsuwan N, Satitpitakul V, Changul T, Jariyakosol S. Incidence and pattern of dry eye after cataract surgery. PLoS One. 2013 Nov 12;8(11):e78657. doi: 10.1371/journal.pone.0078657. eCollection 2013.</citation>
    <PMID>24265705</PMID>
  </reference>
  <reference>
    <citation>Micera A, Di Zazzo A, Esposito G, Longo R, Foulsham W, Sacco R, Sgrulletta R, Bonini S. Age-Related Changes to Human Tear Composition. Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):2024-2031. doi: 10.1167/iovs.17-23358.</citation>
    <PMID>29677365</PMID>
  </reference>
  <reference>
    <citation>Di Zazzo A, Micera A, De Piano M, Cortes M, Bonini S. Tears and ocular surface disorders: Usefulness of biomarkers. J Cell Physiol. 2019 Jul;234(7):9982-9993. doi: 10.1002/jcp.27895. Epub 2018 Dec 4. Review.</citation>
    <PMID>30515814</PMID>
  </reference>
  <reference>
    <citation>Olivieri F, Prattichizzo F, Grillari J, Balistreri CR. Cellular Senescence and Inflammaging in Age-Related Diseases. Mediators Inflamm. 2018 Apr 17;2018:9076485. doi: 10.1155/2018/9076485. eCollection 2018.</citation>
    <PMID>29849499</PMID>
  </reference>
  <reference>
    <citation>Baker JR, Vuppusetty C, Colley T, Hassibi S, Fenwick PS, Donnelly LE, Ito K, Barnes PJ. MicroRNA-570 is a novel regulator of cellular senescence and inflammaging. FASEB J. 2019 Feb;33(2):1605-1616. doi: 10.1096/fj.201800965R. Epub 2018 Aug 29.</citation>
    <PMID>30156909</PMID>
  </reference>
  <reference>
    <citation>Ventura MT, Casciaro M, Gangemi S, Buquicchio R. Immunosenescence in aging: between immune cells depletion and cytokines up-regulation. Clin Mol Allergy. 2017 Dec 14;15:21. doi: 10.1186/s12948-017-0077-0. eCollection 2017. Review.</citation>
    <PMID>29259496</PMID>
  </reference>
  <reference>
    <citation>Torricelli AA, Santhiago MR, Wilson SE. Topical cyclosporine a treatment in corneal refractive surgery and patients with dry eye. J Refract Surg. 2014 Aug;30(8):558-64. doi: 10.3928/1081597X-20140711-09.</citation>
    <PMID>25325897</PMID>
  </reference>
  <reference>
    <citation>Di Zazzo A, Micera A, Coassin M, Varacalli G, Foulsham W, De Piano M, Bonini S. InflammAging at Ocular Surface: Clinical and Biomolecular Analyses in Healthy Volunteers. Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1769-1775. doi: 10.1167/iovs.18-25822.</citation>
    <PMID>31022299</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campus Bio-Medico University</investigator_affiliation>
    <investigator_full_name>Antonio Di Zazzo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ocular surface disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Screening visit (-30 days)&#xD;
Cataract surgery&#xD;
visit 1 ( 7 days after surgery)&#xD;
visit 2 (15 days after surgery)&#xD;
visit 3 (45 days after surgery),&#xD;
last follow up (90 days after surgery)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

